Fractyl Health develops novel surgical tools for the treatment of metabolic disease.

The company is developing durable therapies that address root causes of obesity and type 2 diabetes. Its lead asset, Revita, is an outpatient endoscopic procedure targeting duodenal dysfunction. By resurfacing the diseased duodenal lining, Revita aims to reset abnormal nutrient sensing and gut-brain signaling that drive weight regain and insulin resistance. Revita holds FDA Breakthrough Device designation and early clinical data suggest the procedure delivers efficacy for weight loss maintenance with excellent safety. The technology positions Fractyl as a potential leader in a $175B untapped market for post-GLP-1 weight loss maintenance. Fractyl’s second platform, Rejuva, is a preclinical intrapancreatic gene therapy intended to restore lasting metabolic control for patients with Type 2 diabetes, by durably resetting pancreatic biology.